Interparfums Reports Record 2024 Full Year Results, Exceeds EPS Guidance, and Increases Dividend

IPAR
September 20, 2025
Interparfums, Inc. reported record results for the fourth quarter and full year ended December 31, 2024. The company achieved diluted earnings per share (EPS) of $5.12, or $5.18 before a previously communicated non-recurring, non-cash impairment loss of $4 million for Rochas Fashion, surpassing its guidance of $5.15. Consolidated gross margin for the year expanded by 20 basis points to 63.9% from 63.7% in 2023. Operating income before impairment loss increased 11% to $279 million, resulting in an operating profit margin of 19.2%, up slightly from 19.1% in 2023. The company ended the year with a strong financial position, including $235 million in cash, cash equivalents, and short-term investments, and significantly improved operating cash flow, which was equivalent to 92% of net income, up from 56% in 2023. The Board of Directors approved a 7% increase in the annual cash dividend rate to $3.20 per share, up from $3.00 per share, reflecting confidence in the company's financial strength and ability to achieve long-term growth. The next quarterly cash dividend of $0.80 per share is payable on March 28, 2025. Interparfums reaffirmed its 2025 guidance, projecting net sales of $1.51 billion and diluted EPS of $5.35, both representing a 4% increase. This guidance assumes that the average dollar/euro exchange rate remains at current levels. The company announced plans to launch its first proprietary niche brand, Solférino, in the summer of 2025, with an ultra-selective distribution strategy including its own boutique in Paris later in the year. This initiative aims to tap into the high-end fragrance market and gain insights applicable across its portfolio. The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.